Description

1-Cyclopropyl-6-Fluoro-5-Methyl-7-(3-Methylpiperazin-1-Yl)-4-Oxo-2,3-Dihydroquinoline-3-Carboxylic Acid Hydrochloride is a high-purity pharmaceutical intermediate of significant commercial and research importance. Its value lies in its role as a key synthetic precursor for advanced fluoroquinolone antibiotics, enabling the development of next-generation antimicrobial agents. This compound is essential for pharmaceutical R&D laboratories, API (Active Pharmaceutical Ingredient) manufacturers, and fine chemical suppliers serving the global healthcare sector.

Application

• Key Intermediate for Antibiotic Synthesis: Primarily used in the production of novel fluoroquinolone antibiotics, such as garenoxacin and its analogs.
• Pharmaceutical Research & Development: Serves as a critical building block in medicinal chemistry programs targeting bacterial DNA gyrase and topoisomerase IV inhibitors.
• Active Pharmaceutical Ingredient (API) Manufacturing: Employed in the scaled-up synthesis of finished drug substances under current Good Manufacturing Practices (cGMP).
• Reference Standard: Used as a high-purity analytical standard for quality control and regulatory compliance testing in pharmaceutical production.
• Process Chemistry Optimization: Utilized for developing and optimizing efficient, cost-effective synthetic routes for complex quinolone derivatives.

Basic Information

Item	Details
Product Name	1-Cyclopropyl-6-Fluoro-5-Methyl-7-(3-Methylpiperazin-1-Yl)-4-Oxo-2,3-Dihydroquinoline-3-Carboxylic Acid Hydrochloride
CAS No.	173689-78-6
Molecular Formula	C20H23FN4O3 · HCl
Molecular Weight	422.88 g/mol (Free base: 386.42 g/mol)
Synonyms	Garenoxacin Intermediate; Garenoxacin Impurity; DW-224a Hydrochloride; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic Acid Hydrochloride; 7-(3-Methylpiperazin-1-yl)-1-cyclopropyl-6-fluoro-5-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride; BMS-284756 Intermediate; T-3811 Intermediate
EINECS	Contact for details

Quality Control

Our production of this pharmaceutical intermediate adheres to stringent quality management systems. Every batch is subjected to comprehensive analytical testing, including HPLC for purity and related substances, NMR and IR for structural confirmation, and residual solvent analysis to ensure compliance with ICH guidelines. A detailed Certificate of Analysis (COA) is provided with each shipment, and custom synthesis under cGMP conditions is available upon request.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed to prevent moisture absorption. For long-term storage, consider desiccants or an inert atmosphere.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Retention time corresponds to reference standard
Identification (IR)	Spectrum matches reference
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0%; Any single unknown impurity ≤0.5%
Water Content (KF)	≤1.0%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.